Compare Orchid Chemicals with Novartis - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ORCHID PHARMA LTD vs NOVARTIS - Comparison Results

ORCHID PHARMA LTD     Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ORCHID PHARMA LTD NOVARTIS ORCHID PHARMA LTD/
NOVARTIS
 
P/E (TTM) x -0.5 493.6 - View Chart
P/BV x 0.1 28.6 0.4% View Chart
Dividend Yield % 0.0 1.6 -  

Financials

 ORCHID PHARMA LTD   NOVARTIS
EQUITY SHARE DATA
    ORCHID PHARMA LTD
Sep-13
NOVARTIS
Mar-18
ORCHID PHARMA LTD/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs194758 25.6%   
Low Rs35579 6.0%   
Sales per share (Unadj.) Rs276.5228.4 121.1%  
Earnings per share (Unadj.) Rs-79.231.7 -249.6%  
Cash flow per share (Unadj.) Rs-43.532.8 -132.6%  
Dividends per share (Unadj.) Rs010.00 0.0%  
Dividend yield (eoy) %01.5 0.0%  
Book value per share (Unadj.) Rs53.9297.1 18.2%  
Shares outstanding (eoy) m70.4524.69 285.3%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x0.42.9 14.1%   
Avg P/E ratio x-1.421.1 -6.9%  
P/CF ratio (eoy) x-2.620.4 -12.9%  
Price / Book Value ratio x2.12.2 94.4%  
Dividend payout %031.5 0.0%   
Avg Mkt Cap Rs m8,06716,505 48.9%   
No. of employees `0002.80.7 419.2%   
Total wages/salary Rs m2,5271,445 174.8%   
Avg. sales/employee Rs Th6,956.18,441.3 82.4%   
Avg. wages/employee Rs Th902.52,163.6 41.7%   
Avg. net profit/employee Rs Th-1,993.01,173.1 -169.9%   
INCOME DATA
Net Sales Rs m19,4775,639 345.4%  
Other income Rs m4071,718 23.7%   
Total revenues Rs m19,8847,357 270.3%   
Gross profit Rs m1,103-63 -1,764.2%  
Depreciation Rs m2,51925 9,957.3%   
Interest Rs m5,22755 9,451.7%   
Profit before tax Rs m-6,2361,575 -395.9%   
Minority Interest Rs m200-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m5110-   
Tax Rs m-125792 -15.8%   
Profit after tax Rs m-5,580784 -712.1%  
Gross profit margin %5.7-1.1 -510.7%  
Effective tax rate %2.050.3 4.0%   
Net profit margin %-28.713.9 -206.2%  
BALANCE SHEET DATA
Current assets Rs m11,0149,522 115.7%   
Current liabilities Rs m32,0603,296 972.7%   
Net working cap to sales %-108.1110.4 -97.9%  
Current ratio x0.32.9 11.9%  
Inventory Days Days9537 259.1%  
Debtors Days Days3428 118.1%  
Net fixed assets Rs m29,44046 63,999.8%   
Share capital Rs m705123 570.9%   
"Free" reserves Rs m2,0437,213 28.3%   
Net worth Rs m3,8007,336 51.8%   
Long term debt Rs m9,0180-   
Total assets Rs m46,51011,105 418.8%  
Interest coverage x-0.229.5 -0.7%   
Debt to equity ratio x2.40-  
Sales to assets ratio x0.40.5 82.5%   
Return on assets %-0.87.6 -10.1%  
Return on equity %-146.910.7 -1,374.9%  
Return on capital %-3.722.2 -16.8%  
Exports to sales %37.90-   
Imports to sales %22.60-   
Exports (fob) Rs m7,378NA-   
Imports (cif) Rs m4,406NA-   
Fx inflow Rs m7,51361 12,398.2%   
Fx outflow Rs m5,6493,630 155.6%   
Net fx Rs m1,865-3,570 -52.2%   
CASH FLOW
From Operations Rs m1,6821,610 104.5%  
From Investments Rs m-9,860687 -1,435.3%  
From Financial Activity Rs m6,644-2,677 -248.2%  
Net Cashflow Rs m-1,535-380 404.4%  

Share Holding

Indian Promoters % 32.3 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 4.6 2.0 230.0%  
FIIs % 3.3 1.6 206.3%  
ADR/GDR % 4.6 0.0 -  
Free float % 55.3 21.5 257.2%  
Shareholders   84,811 41,647 203.6%  
Pledged promoter(s) holding % 54.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ORCHID PHARMA LTD With:   TORRENT PHARMA  NATCO PHARMA  DIVIS LABORATORIES  PIRAMAL ENTERPRISES  UNICHEM LAB  

Compare ORCHID PHARMA LTD With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Tanks 642 Points; Automobile and Realty Stocks Plunge(Closing)

Indian share markets fell sharply today amid fears of rising crude oil prices and weakness in the rupee rattled investor sentiment.

Related Views on News

NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (4QFY19); Net Profit Down 26.2% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, NOVARTIS has posted a net profit of Rs 195 m (down 26.2% YoY). Sales on the other hand came in at Rs 1 bn (down 11.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (3QFY19); Net Profit Down 31.3% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, NOVARTIS has posted a net profit of Rs 129 m (down 31.3% YoY). Sales on the other hand came in at Rs 1 bn (down 13.1% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

ORCHID PHARMA LTD Announces Quarterly Results (2QFY19); Net Profit Up 67.1% (Quarterly Result Update)

Jan 31, 2019 | Updated on Jan 31, 2019

For the quarter ended September 2018, ORCHID PHARMA LTD has posted a net profit of Rs 231 m (up 67.1% YoY). Sales on the other hand came in at Rs 1 bn (down 31.9% YoY). Read on for a complete analysis of ORCHID PHARMA LTD's quarterly results.

NOVARTIS Announces Quarterly Results (2QFY19); Net Profit Down 64.1% (Quarterly Result Update)

Nov 21, 2018 | Updated on Nov 21, 2018

For the quarter ended September 2018, NOVARTIS has posted a net profit of Rs 94 m (down 64.1% YoY). Sales on the other hand came in at Rs 1 bn (down 36.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ORCHID PHARMA LTD SHARE PRICE


Jul 24, 2019 (Close)

TRACK ORCHID PHARMA LTD

  • Track your investment in ORCHID PHARMA LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ORCHID PHARMA LTD

ORCHID PHARMA LTD - TORRENT PHARMA COMPARISON

COMPARE ORCHID PHARMA LTD WITH

MARKET STATS